Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial | SpringerLink
Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA's Fast Track Designation
fruquintinib – The New Economy
Trinity Delta 2020 set to be the "breakthrough" year - Trinity Delta
Efficacy of fruquintinib confirmed in refractory metastatic colorectal cancer - Medical Update Online
Fruquintinib API Manufacturer and Supplier | CAS 1194506-26-7 - Dr. Reddy's
Chi-Med goes global
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China | BMC Cancer | Full Text
China Approves Home-Grown Colon Cancer Drug - Asian Scientist Magazine
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China | BMC Cancer | Full Text
China Approves Home-Grown Colon Cancer Drug - Asian Scientist Magazine